These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15006823)

  • 1. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials.
    Lobo RA
    Arch Intern Med; 2004 Mar; 164(5):482-4. PubMed ID: 15006823
    [No Abstract]   [Full Text] [Related]  

  • 2. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women.
    Rosano GM; Maffei S; Andreassi MG; Vitale C; Vassalle C; Gambacciani M; Stramba-Badiale M; Mercuro G
    J Cardiovasc Med (Hagerstown); 2009 Jan; 10(1):85-92. PubMed ID: 19145119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence.
    Harman SM; Naftolin F; Brinton EA; Judelson DR
    Ann N Y Acad Sci; 2005 Jun; 1052():43-56. PubMed ID: 16024750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hormone replacement therapy and cardiovascular prevention: many statements, some doubts].
    Motolese M
    Ital Heart J Suppl; 2003 Jul; 4(7):545-58. PubMed ID: 14558283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women.
    Alexandersen P; Tankó LB; Bagger YZ; Qin G; Christiansen C
    Climacteric; 2006 Apr; 9(2):108-18. PubMed ID: 16698657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health risks after cessation of postmenopausal hormone therapy.
    Pines A; Sturdee D; Birkhäuser M;
    Climacteric; 2008 Jun; 11(3):179-80. PubMed ID: 18568782
    [No Abstract]   [Full Text] [Related]  

  • 7. Hormone therapy and selective estrogen receptor modulators for prevention of coronary heart disease in postmenopausal women estrogen replacement from the cardiologist's perspective.
    Mobasseri S; Liebson PR; Klein LW
    Cardiol Rev; 2004; 12(6):287-98. PubMed ID: 15476565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.
    Prentice RL; Langer R; Stefanick ML; Howard BV; Pettinger M; Anderson G; Barad D; Curb JD; Kotchen J; Kuller L; Limacher M; Wactawski-Wende J;
    Am J Epidemiol; 2005 Sep; 162(5):404-14. PubMed ID: 16033876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results.
    Kuhl H; Stevenson J
    Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmenopausal hormone therapy and the risk of cardiovascular disease.
    Stramba-Badiale M
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):303-9. PubMed ID: 19430340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
    Brinton RD
    Ann N Y Acad Sci; 2005 Jun; 1052():57-74. PubMed ID: 16024751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learned from the WHI: HRT requires a cautious and individualized approach.
    Aubuchon M; Santoro N
    Geriatrics; 2004 Nov; 59(11):22-6. PubMed ID: 15615157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Postmenopausal hormone replacement therapy and cardiovascular disease].
    Høibraaten E
    Tidsskr Nor Laegeforen; 2002 Jun; 122(16):1564-5. PubMed ID: 12119783
    [No Abstract]   [Full Text] [Related]  

  • 14. Hormone therapy and cardiovascular disease in the early postmenopause: the WHI data revisited.
    Pines A; Sturdee DW; Birkhäuser MH;
    Climacteric; 2007 Jun; 10(3):195-6. PubMed ID: 17487646
    [No Abstract]   [Full Text] [Related]  

  • 15. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.
    Prentice RL; Langer RD; Stefanick ML; Howard BV; Pettinger M; Anderson GL; Barad D; Curb JD; Kotchen J; Kuller L; Limacher M; Wactawski-Wende J;
    Am J Epidemiol; 2006 Apr; 163(7):589-99. PubMed ID: 16484450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmenopausal hormone therapy: new questions and the case for new clinical trials.
    Manson JE; Bassuk SS; Harman SM; Brinton EA; Cedars MI; Lobo R; Merriam GR; Miller VM; Naftolin F; Santoro N
    Menopause; 2006; 13(1):139-47. PubMed ID: 16607110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The complex interplay of vasomotor symptoms, hormone therapy, and cardiovascular risk.
    Allison MA; Manson JE
    Menopause; 2009; 16(4):619-20. PubMed ID: 19503007
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
    Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
    J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmenopausal hormone therapy and the risk of cardiovascular disease.
    Bittner V
    Expert Opin Pharmacother; 2009 Sep; 10(13):2041-53. PubMed ID: 19563274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WHI risks: any relevance to menopause management?
    Burger HG
    Maturitas; 2007 May; 57(1):6-10. PubMed ID: 17368974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.